The Pharmacological Basis for Metrifonate’s Favourable Tolerability in the Treatment of Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9824|9|2|15-19

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.9, Iss.2, 1998-07, pp. : 15-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Observational Clinical Study of the Efficacy and Tolerability of Donepezil in the Treatment of Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 4, 2003-03 ,pp. : 189-198

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite

Effect of the Apolipoprotein E ε4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 21, Iss. 1, 2005-12 ,pp. : 33-39

Karger

Access to resources Recommend Favorite

Beyond the Cholinergic Hypothesis: The Effect of Metrifonate and Other Cholinesterase Inhibitors on Neuropsychiatric Symptoms in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 9, Iss. 2, 1998-07 ,pp. : 8-14

Karger

Access to resources Recommend Favorite